MAYNE PHARMA ANNOUNCES FDA APPROVAL OF MITOXANTRONE

Mayne Pharma has announced that the FDA has granted final approval for the company's abbreviated new drug application for Mitoxantrone injection in 20 mg, 25 mg and 30 mg multiple-dose formulations.

Mitoxantrone is a generic equivalent to Serono's multiple sclerosis drug Novantrone.